Can activated beta-catenin (ABV) be used as a marker to predict aggressive osteosarcoma and progression to metastatic disease?

活化的β-连环蛋白（ABV）可以作为预测侵袭性骨肉瘤和转移性疾病进展的标志物吗？

• 批准号: 466547
• 负责人: Hinton Kristin
• 金额: $ 1.27万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466547&lang=en
• 关键词: Activated Beta-Catenin; Metastasis; Osteosarcoma; Prognostic Factor

Osteosarcoma is a rare primary bone tumor with a peak incidence in children and young adults. Metastatic spread is detected in about 20% of patients on presentation, typically in the lungs. Currently there are no specific laboratory tests to indicate whet

骨肉瘤是一种罕见的原发性骨肿瘤，在儿童和年轻人中发病率最高。在约20%的患者中检测到转移性扩散，通常在肺部。目前还没有具体的实验室测试表明，